drugset
drugset / Trial / NCT06145412

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

NCT06145412 ↗

Phase 2 Active not recruiting 4 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether treatment with Xevinapant added to standard chemoradiation after surgery is an effective treatment for people with high-risk head and neck cancers.

Timeline

Start
2023-11-16
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Xevinapant Small molecule 200 mg Oral
Background Cisplatin Other / unclassified 100 mg/m2 —

Indications

head and neck cancer